MDM36 Antibody

What is MDM36 and why is it significant for mitochondrial research?

MDM36 (Mitochondrial Distribution and Morphology protein 36) is a novel component of mitochondrial fission in yeast that promotes the formation of attachment sites for mitochondria at the cell cortex. Genetic and cytological studies indicate that MDM36 facilitates the creation of Dnm1- and Num1-containing structures that are crucial for dynamin-mediated membrane fission, effectively linking mitochondrial motility and division . MDM36 deletion mutants (Δmdm36) display highly interconnected mitochondrial networks that closely resemble those seen in known fission mutants. Additionally, mitochondrial fission induced by actin cytoskeleton depolymerization is blocked in Δmdm36 mutants, and the number of Dnm1 clusters on mitochondrial tips is reduced . These characteristics make MDM36 an essential protein for understanding the mechanisms of mitochondrial dynamics and morphology.

How can MDM36 antibodies be validated for specificity in yeast studies?

MDM36 antibody validation should employ multiple complementary strategies to ensure specificity. Begin with Western blotting using wild-type and Δmdm36 yeast extracts, where a specific antibody should detect a band of the expected molecular weight in wild-type but not in the deletion mutant. For further validation, implement peptide competition assays where pre-incubation of the antibody with a specific blocking peptide corresponding to MDM36 should abolish the signal in immunoblotting or immunofluorescence .

Additionally, consider using recombinant expression systems with tagged MDM36 as positive controls. Validation can be enhanced through immunoprecipitation followed by mass spectrometry to verify that the antibody captures MDM36. Similar to the approach used for validating other antibodies, ELISA-based methods can be employed to quantitatively assess antibody specificity when purified MDM36 protein is available .

What are the optimal sample preparation techniques for detecting MDM36 in subcellular fractions?

For efficient detection of MDM36 in subcellular fractions, implement a differential centrifugation protocol followed by sucrose gradient centrifugation as described in previous studies . Begin by isolating mitochondria through differential centrifugation based on the Daum protocol. Further purify these isolates using sucrose gradient centrifugation (SW-40 rotor, 40,000 rpm for 30 min at 4°C) to achieve high-purity mitochondrial fractions .

For analyzing MDM36 binding to mitochondria, resuspend 200 μg of purified mitochondria in 200 μl of import buffer (50 mM HEPES/KOH, pH 7.2, 3% fatty acid-free bovine serum albumin, 0.5 M sorbitol, 80 mM KCl, 10 mM magnesium acetate, 2 mM MnCl₂, and 2 mM potassium phosphate, pH 7.2). Incubate for 5 min at 25°C with 5 mM NADH, 2.5 mM ATP, 10 mM phosphocreatine, and 100 μg/ml creatine kinase to maintain mitochondrial integrity during the procedure . After separation, detect MDM36 through SDS-PAGE followed by Western blotting with appropriate antibodies.

What controls should be included when performing immunofluorescence with MDM36 antibodies?

When performing immunofluorescence with MDM36 antibodies, include the following essential controls:

• Negative genetic control: Utilize Δmdm36 deletion strains to establish baseline signal and confirm antibody specificity.

• Peptide competition control: Pre-incubate the MDM36 antibody with specific blocking peptides to verify that the observed signal is specifically due to MDM36 detection, similar to the peptide competition approach used for histone modification antibodies .

• Co-localization controls: Include markers for mitochondria (such as mtRFP) and cell cortex structures to verify the expected localization pattern of MDM36 at the interface between mitochondria and the cell cortex.

• Antibody concentration gradient: Perform a dilution series of primary antibody to determine optimal signal-to-noise ratio and avoid non-specific binding.

• Secondary antibody-only control: Incubate samples with secondary antibody alone to assess background fluorescence levels.

These controls collectively ensure reliable and interpretable immunofluorescence results when studying MDM36 localization and interactions in yeast cells.

How can MDM36 antibodies be used to study the interaction between MDM36 and Num1?

To investigate MDM36-Num1 interactions, implement co-immunoprecipitation (co-IP) studies using MDM36 antibodies coupled to protein A/G beads. This approach allows for the isolation of intact protein complexes from yeast cell lysates. Based on the evidence that MDM36 enhances Num1 clustering at the cell cortex , the co-IP should reveal direct or indirect interactions between these proteins.

For more sophisticated analysis, combine co-IP with proximity ligation assays (PLA) to visualize interaction sites in situ. This technique involves using primary antibodies against both MDM36 and Num1, followed by secondary antibodies conjugated with complementary oligonucleotides that, when in close proximity, generate a fluorescent signal after ligation and amplification.

Additionally, implement immunofluorescence co-localization studies using high-resolution microscopy techniques such as structured illumination microscopy (SIM) or stimulated emission depletion (STED) microscopy. These approaches can precisely map the spatial relationship between MDM36 and Num1 clusters at the cell cortex. The research has shown that colocalization of Num1 and Dnm1 is abolished in the absence of MDM36, providing support for the importance of these interactions in mitochondrial fission .

What quantitative methods can be used with MDM36 antibodies to assess protein levels in different experimental conditions?

Several quantitative methods using MDM36 antibodies can accurately measure protein levels across experimental conditions:

• Quantitative Western Blotting: Implement fluorescent secondary antibodies or chemiluminescence detection with standard curves using recombinant MDM36. Normalize signals to stable housekeeping proteins and use digital imaging systems for quantification, similar to approaches used for other proteins .

• Flow Cytometry: For cellular MDM36 quantification, permeabilize fixed cells and stain with fluorescently labeled MDM36 antibodies. This allows for high-throughput analysis of protein levels across thousands of individual cells.

• ELISA-Based Quantification: Develop a sandwich ELISA using immobilized capture antibodies against MDM36 and detection antibodies conjugated with enzymes. This approach enables precise quantification of MDM36 in cell lysates or subcellular fractions.

• Absolute Quantification by Mass Spectrometry: Combine immunoprecipitation using MDM36 antibodies with selected reaction monitoring (SRM) mass spectrometry using isotope-labeled peptide standards for absolute quantification of MDM36.

For comparing MDM36 levels between wild-type and experimentally manipulated cells (such as overexpression systems), ensure identical sample preparation and loading controls. When studying MDM36's role in clustering Num1, quantitative microscopy techniques can be employed to measure fluorescence intensities of tagged proteins, following methods similar to those used for measuring Num1-GFP intensities relative to standard proteins like Cse4-GFP .

How can ChIP-seq approaches be adapted using MDM36 antibodies to study genome interactions?

While MDM36 is primarily known for its role in mitochondrial dynamics rather than as a nuclear protein, adapting ChIP-seq approaches using MDM36 antibodies could potentially reveal unexpected nuclear functions or interactions. To implement this experimental approach:

• Chromatin Preparation: Cross-link yeast cells with formaldehyde (1% final concentration) for 10-15 minutes at room temperature. Quench with glycine, then lyse cells and sonicate chromatin to 200-500 bp fragments.

• Immunoprecipitation Optimization: Test various MDM36 antibody concentrations and incubation conditions. Include appropriate controls such as IgG negative control and a positive control antibody against a known DNA-binding protein.

• Sequential ChIP: If MDM36 might be part of a complex that interacts with DNA, consider sequential ChIP (ChIP-reChIP) where chromatin is first immunoprecipitated with antibodies against known DNA-binding proteins, followed by MDM36 antibodies.

• Data Validation: Validate any DNA binding or chromatin association results with orthogonal techniques such as DNA-protein binding assays, protein tethering experiments, or localization studies using subcellular fractionation.

• Bioinformatic Analysis: Apply peak calling algorithms optimized for factors with potentially weak or transient interactions, and intersect results with known mitochondrial DNA-associated regions to examine possible dual roles.

This approach would need extensive validation, particularly given MDM36's established role in mitochondrial dynamics. Include Δmdm36 strains as negative controls to distinguish between specific and non-specific antibody interactions with chromatin.

What techniques can be used for studying the dynamics of MDM36-dependent protein complexes in real-time?

To study the dynamics of MDM36-dependent protein complexes in real-time, implement these advanced microscopy and biochemical approaches:

• Live-Cell FRET (Förster Resonance Energy Transfer): Engineer yeast strains expressing MDM36 and interacting partners (like Num1 or Dnm1) tagged with compatible fluorophores (e.g., CFP/YFP pairs). FRET measurements can detect real-time protein interactions at the cell cortex during mitochondrial fission events.

• Fluorescence Recovery After Photobleaching (FRAP): Apply this technique to fluorescently tagged MDM36 or its binding partners to measure protein turnover rates and complex stability at cellular attachment sites. This approach can determine whether MDM36 overexpression affects the mobility of Num1, as suggested by research showing enhanced Num1 clustering in Mdm36 OX cells .

• Single-Molecule Tracking: Implement photo-activatable fluorescent proteins fused to MDM36 to track individual molecules, revealing movement patterns and residence times at cortical sites.

• Proximity Biotinylation (BioID or TurboID): Fuse MDM36 to a promiscuous biotin ligase to identify proximal proteins in living cells. Time-course experiments can map dynamic changes in the MDM36 interactome during different cellular states or in response to stimuli.

• Lattice Light-Sheet Microscopy: This technique provides high-resolution 3D imaging with reduced phototoxicity, allowing for extended visualization of MDM36-dependent structures during mitochondrial fission events.

• Correlative Light and Electron Microscopy (CLEM): Combine fluorescence imaging of tagged MDM36 with electron microscopy to visualize ultrastructural details of MDM36-containing protein complexes at the cell cortex.

These methods can reveal how MDM36-dependent structures form and function in linking mitochondrial dynamics to the cell cortex, providing insights into the temporal sequence of events during mitochondrial fission.

How should experiments be designed to compare wild-type and mdm36Δ phenotypes using antibody-based approaches?

When designing experiments to compare wild-type and mdm36Δ phenotypes using antibody-based approaches, implement a comprehensive strategy that addresses multiple aspects of mitochondrial morphology and function:

• Strain Validation: Confirm mdm36Δ deletion by PCR and Western blotting using MDM36 antibodies to verify complete absence of the protein in mutant strains.

• Mitochondrial Morphology Analysis: Perform immunofluorescence microscopy using antibodies against mitochondrial markers (e.g., porin) in parallel with MDM36 staining. Quantify morphological parameters including network connectivity, branch length, and mitochondrial distribution. Studies have shown that mdm36Δ mutants contain highly interconnected mitochondrial networks resembling known fission mutants .

• Cortical Attachment Quantification: Use immunofluorescence to quantify Num1 and Dnm1 localization patterns. Previous research has shown that colocalization of Num1 and Dnm1 is abolished in the absence of MDM36 , so antibodies against these proteins can reveal key differences between wild-type and mutant strains.

• Functional Assays with Cytoskeletal Disruption: Include treatments that depolymerize the actin cytoskeleton (e.g., Latrunculin A) to assess mitochondrial fission capacity, as this process is blocked in mdm36Δ mutants .

• Double Mutant Analysis: Create and analyze double mutants lacking MDM36 and fusion-promoting components (e.g., Fzo1, Mdm30) to study genetic interactions, following previous findings that MDM36 acts antagonistically to these fusion-promoting components .

• Controls and Replicates: Include multiple biological and technical replicates with appropriate statistical analysis. Use unrelated deletion mutants as additional controls to confirm specificity of observed phenotypes.

By systematically comparing these parameters between wild-type and mdm36Δ strains, researchers can comprehensively characterize the role of MDM36 in mitochondrial dynamics and cortical attachment.

What are key considerations when choosing between polyclonal and monoclonal antibodies for MDM36 detection?

When selecting between polyclonal and monoclonal antibodies for MDM36 detection, researchers should consider these critical factors:

Polyclonal Antibodies for MDM36:

• Advantages: Recognize multiple epitopes on MDM36, increasing detection sensitivity and tolerance to minor protein denaturation or modifications. Particularly valuable for low-abundance proteins like MDM36.

• Considerations: May exhibit batch-to-batch variation requiring standardization across experiments. Higher potential for cross-reactivity with related proteins.

• Optimal Applications: Western blotting, immunoprecipitation, and initial characterization studies where sensitivity is prioritized.

Monoclonal Antibodies for MDM36:

• Advantages: Provide consistent specificity for a single epitope, reducing background and enabling precise quantification. Essential for distinguishing between closely related protein isoforms.

• Considerations: May lose reactivity if the target epitope is masked or modified under certain experimental conditions. Potentially less sensitive than polyclonal antibodies.

• Optimal Applications: Quantitative immunofluorescence, flow cytometry, and studies requiring high reproducibility over extended periods.

Critical Decision Factors:

• Experimental Purpose: Choose polyclonal antibodies for discovery-phase research and monoclonal antibodies for standardized assays.

• Epitope Accessibility: Consider the cellular localization of MDM36 at mitochondria-cortex interfaces when selecting antibodies with appropriate epitope recognition.

• Validation Requirements: Follow complementary validation strategies similar to those used for other antibodies, including peptide competition assays and genetic knockouts.

• Application Compatibility: Test both types in preliminary experiments to determine which performs optimally in your specific application.

The selection between polyclonal and monoclonal antibodies should be guided by the specific research questions and methodological requirements of the study.

How can immunoprecipitation with MDM36 antibodies facilitate the identification of novel interaction partners?

Immunoprecipitation (IP) with MDM36 antibodies offers a powerful approach for discovering novel interaction partners within the mitochondrial fission machinery. To effectively implement this strategy:

• Optimization of Lysis Conditions: Test multiple buffer compositions (varying detergent types and concentrations) to preserve native protein interactions while efficiently extracting MDM36-containing complexes from the cell cortex-mitochondrial interface. Consider crosslinking approaches to capture transient interactions.

• Antibody Selection and Validation: Choose antibodies that recognize native MDM36 conformations rather than just denatured epitopes. Validate IP efficiency using known interactions, such as with Num1 or Dnm1, before proceeding to discovery experiments .

• Experimental Design for Discovery:

  • Forward IP: Use MDM36 antibodies to capture complexes, followed by mass spectrometry identification of co-precipitated proteins.

  • Reverse IP: Validate identified interactions by performing IP with antibodies against newly identified partners and detecting MDM36 in the precipitate.

  • Controls: Include Δmdm36 strains as negative controls to identify non-specific binding.

• Quantitative Proteomics Approach: Implement SILAC (Stable Isotope Labeling with Amino acids in Cell culture) or TMT (Tandem Mass Tag) labeling to quantitatively compare protein abundances in MDM36 immunoprecipitates versus controls.

• Functional Validation of Interactions: After identifying potential partners, validate their biological relevance through genetic approaches (e.g., creating double mutants) and localization studies (e.g., co-localization analysis).

• Network Analysis: Place newly identified interactions in the context of known mitochondrial fission and fusion pathways to develop comprehensive models of MDM36 function.

This systematic approach can reveal previously unrecognized components of the mitochondrial fission machinery and provide insights into how MDM36 facilitates the formation of Dnm1- and Num1-containing structures at the cell cortex.

What strategies should be employed when using MDM36 antibodies for tissue immunohistochemistry?

While MDM36 is primarily studied in yeast, researchers investigating potential homologs in higher organisms should consider these specialized strategies for tissue immunohistochemistry:

• Fixation Optimization: Test multiple fixation protocols to determine optimal conditions for preserving MDM36 epitopes while maintaining tissue architecture:

  • 4% paraformaldehyde for 24-48 hours at 4°C

  • Methanol-acetone (1:1) for 10 minutes at -20°C

  • Evaluate heat-induced epitope retrieval methods using citrate (pH 6.0) or EDTA (pH 9.0) buffers

• Antibody Validation Controls:

  • Implement peptide competition assays similar to those used for validating histone modification antibodies

  • Include tissues from knockout models (if available) as negative controls

  • Use multiple antibodies targeting different epitopes to confirm staining patterns

• Signal Enhancement and Background Reduction:

  • Employ tyramide signal amplification for low-abundance targets

  • Include blocking steps with appropriate serum (5-10%) and 0.1-0.3% Triton X-100

  • Use avidin-biotin blocking if implementing biotinylated secondary antibodies

• Multiplex Immunostaining Strategy:

  • Combine MDM36 antibodies with markers for mitochondria (e.g., TOMM20), cell boundaries, and potential interacting partners

  • Implement sequential immunostaining with antibody stripping between rounds

  • Consider spectral imaging to resolve multiple fluorophores in spatially overlapping structures

• Quantification Approaches:

  • Develop automated image analysis workflows to quantify staining intensity and pattern

  • Implement machine learning algorithms for unbiased classification of staining patterns

  • Correlate staining patterns with tissue and cellular morphological features

These approaches can be adapted from methods demonstrated to be effective for other antibodies in immunohistochemistry applications, such as those used for detecting post-translational modifications or cell surface proteins .

How should researchers interpret contradictory results from different MDM36 antibodies?

When faced with contradictory results from different MDM36 antibodies, implement this systematic troubleshooting and interpretation framework:

• Epitope Mapping Analysis:

  • Determine recognized epitopes for each antibody through peptide arrays or epitope mapping

  • Assess whether epitopes might be differentially masked by protein interactions or post-translational modifications

  • Consider that different antibodies may recognize distinct conformational states of MDM36

• Validation Status Evaluation:

  • Review validation data for each antibody using complementary strategies similar to those described for other antibodies

  • Prioritize results from antibodies validated through genetic approaches (e.g., absence of signal in Δmdm36 strains)

  • Consider performing additional validation experiments specifically targeting the contradictory aspects

• Experimental Condition Assessment:

  • Evaluate whether discrepancies occur under specific experimental conditions (e.g., fixation methods, buffer compositions)

  • Test antibodies side-by-side under identical conditions to directly compare performance

  • Consider whether differences might reflect biological variation rather than technical issues

• Integration of Multiple Approaches:

  • Supplement antibody-based results with non-antibody methods (e.g., tagged proteins, fluorescent protein fusions)

  • Where possible, implement functional assays to determine which antibody results correlate with biological outcomes

  • Use orthogonal techniques to validate key findings from each antibody

• Reporting Recommendations:

  • Transparently report contradictory results in publications

  • Specify exact antibody clones, concentrations, and conditions used

  • Consider whether discrepancies might reveal previously unrecognized biological complexity

By systematically analyzing contradictory results through this framework, researchers can often transform apparent inconsistencies into new insights about MDM36 biology, protein states, or methodological considerations.

What are common pitfalls in interpreting immunofluorescence data for MDM36 localization?

Interpreting immunofluorescence data for MDM36 localization requires awareness of several common pitfalls:

By addressing these common pitfalls, researchers can generate more reliable and informative data about MDM36 localization and its role in linking mitochondrial dynamics to the cell cortex.

How can researchers validate antibody-based findings about MDM36 using complementary non-antibody techniques?

To validate antibody-based findings about MDM36, researchers should implement these complementary non-antibody approaches:

• Genetic Tagging Strategies:

  • Engineer strains expressing MDM36 with fluorescent protein tags (GFP, mCherry) or epitope tags (HA, FLAG) under native promoter control

  • Compare localization patterns between antibody-detected endogenous MDM36 and tagged versions

  • Verify that tagged versions complement Δmdm36 phenotypes to ensure functionality

• Functional Genetic Approaches:

  • Create precise mutations in MDM36 targeting specific domains or interaction sites

  • Assess phenotypic outcomes to validate antibody-detected interactions

  • Implement genetic suppressor screens to identify functional relationships independent of physical detection methods

• Biochemical Interaction Validation:

  • Use purified recombinant proteins to verify direct interactions detected by antibody-based co-immunoprecipitation

  • Implement pull-down assays with tagged proteins expressed in heterologous systems

  • Apply techniques like surface plasmon resonance or isothermal titration calorimetry to quantify interaction parameters

• mRNA Analysis Correlation:

  • Quantify MDM36 mRNA levels using RT-qPCR or RNA-seq

  • Correlate transcript abundance with protein levels detected by antibodies

  • Implement single-cell RNA analysis to capture cell-to-cell variation

• Mass Spectrometry Verification:

  • Use targeted proteomics approaches to quantify MDM36 peptides directly

  • Compare protein amounts and modifications with antibody-based detection methods

  • Implement crosslinking mass spectrometry to map protein interaction interfaces

• Functional Imaging Approaches:

  • Apply techniques like proximity ligation assays or FRET with genetically encoded sensors

  • Use optogenetic tools to manipulate MDM36 function with spatial and temporal precision

  • Implement correlative light and electron microscopy to relate protein localization to ultrastructural features

What factors might influence the specificity of MDM36 antibodies in Western blotting?

Multiple factors can significantly influence the specificity of MDM36 antibodies in Western blotting, requiring careful consideration during experimental design and interpretation:

• Sample Preparation Factors:

  • Protein Denaturation: Insufficient denaturation may preserve protein complexes that mask epitopes or create non-specific bands.

  • Protein Degradation: Proteolytic fragmentation can generate multiple bands that complicate interpretation; use fresh samples with appropriate protease inhibitors.

  • Post-translational Modifications: Phosphorylation, ubiquitination, or other modifications may alter antibody recognition or protein migration patterns.

• Technical Variables:

  • Transfer Efficiency: Incomplete transfer of high molecular weight proteins or excessive transfer of small proteins can affect detection.

  • Blocking Conditions: Inadequate blocking leads to high background; overly stringent blocking may reduce specific signal.

  • Antibody Concentration: Too high concentrations increase non-specific binding; too low concentrations may miss low-abundance targets.

• Buffer and Reagent Considerations:

  • Detergent Selection: Different detergents in lysis buffers can differentially extract MDM36 from membrane-associated complexes.

  • Salt Concentration: Higher salt concentrations may disrupt weak antibody-epitope interactions while reducing non-specific binding.

  • Reducing Agent Strength: Excessive reducing agents may destroy certain epitopes; insufficient reduction may preserve disulfide-linked complexes.

• Antibody-Specific Factors:

  • Clone Selection: For monoclonal antibodies, epitope accessibility in denatured proteins varies between clones.

  • Cross-Reactivity Profile: Antibodies may recognize related proteins, particularly when using polyclonal antibodies.

  • Storage and Handling: Antibody degradation from improper storage or repeated freeze-thaw cycles can alter specificity.

• Validation Approaches:

  • Genetic Controls: Always include Δmdm36 samples as negative controls.

  • Peptide Competition: Pre-incubate antibody with immunizing peptide to confirm specificity, following methods similar to those used for validating other antibodies .

  • Multiple Antibodies: Use antibodies targeting different epitopes to confirm band identity.

By systematically addressing these factors, researchers can optimize Western blotting conditions for specific and reliable detection of MDM36.

What are the emerging trends in antibody-based research for mitochondrial dynamics proteins like MDM36?

Several emerging trends are reshaping antibody-based research for mitochondrial dynamics proteins such as MDM36:

• Super-Resolution Microscopy Integration: Advanced imaging techniques including STED, PALM/STORM, and expansion microscopy are enabling unprecedented resolution of protein complexes at mitochondria-cortex interfaces, revealing nanoscale organization that was previously undetectable with conventional microscopy.

• Single-Cell Proteomics Approaches: Newly developed methods for antibody-based single-cell protein quantification are uncovering cell-to-cell heterogeneity in mitochondrial dynamics proteins, potentially explaining variations in mitochondrial behavior within populations.

• Spatial Proteomics Expansion: Technologies combining antibody detection with spatial transcriptomics are mapping the subcellular organization of mitochondrial fission and fusion machineries with precise spatial context, providing insights into local regulation of mitochondrial dynamics.

• Improved Validation Standards: Following developments in antibody validation, researchers are implementing more rigorous multi-pronged approaches to validate antibodies against mitochondrial proteins, similar to the complementary strategies used for other targets , enhancing research reproducibility.

• Integration with CRISPR Technologies: Combining antibody-based detection with CRISPR-engineered cellular models enables precise correlation between genetic perturbations and protein-level consequences for mitochondrial dynamics proteins.

• Quantitative Interactomics: Advanced proximity labeling approaches coupled with mass spectrometry are mapping dynamic protein interaction networks around mitochondrial fission factors like MDM36, revealing context-dependent changes in protein complexes.

These emerging methodologies promise to enhance our understanding of how proteins like MDM36 function in mitochondrial dynamics and their roles in cellular homeostasis.

What future directions should researchers consider in developing and applying MDM36 antibodies?

Researchers developing and applying MDM36 antibodies should consider these strategic future directions:

• Epitope-Specific Functional Antibodies: Develop antibodies targeting specific functional domains of MDM36, particularly regions mediating interactions with Num1 and Dnm1, potentially enabling selective disruption of specific protein interactions without eliminating the entire protein.

• Conformation-Specific Antibodies: Create antibodies that selectively recognize active versus inactive states of MDM36, providing tools to study the regulation of MDM36 activity during mitochondrial fission events.

• Post-Translational Modification Mapping: Develop modification-specific antibodies to detect potential regulatory modifications of MDM36, since many mitochondrial dynamics proteins are regulated by phosphorylation and other post-translational modifications.

• Cross-Species Compatible Antibodies: Design antibodies recognizing conserved epitopes across species to facilitate translational research between yeast and higher eukaryotes, potentially identifying functional homologs of MDM36.

• Intrabodies for Live-Cell Applications: Engineer antibody fragments (nanobodies or single-chain antibodies) that function in the reducing intracellular environment for live-cell imaging and perturbation studies.

• Therapeutic Exploration in Disease Models: Investigate whether antibodies targeting MDM36 homologs in mammalian systems might have therapeutic potential in diseases associated with mitochondrial dynamics dysregulation.

• Integration with Emerging Technologies: Develop MDM36 antibodies compatible with new techniques like DNA-PAINT super-resolution microscopy or mass cytometry (CyTOF) for multiplexed protein detection.